Dianthus Therapeutics (DNTH) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free DNTH Stock Alerts $27.67 -0.27 (-0.97%) (As of 10:33 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 6:52 PM | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 9.2%Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 9.2%May 14 at 5:36 AM | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $38.00May 13 at 5:38 PM | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 2.4%Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 2.4%May 11, 2024 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up on Analyst UpgradeMay 10, 2024 | marketbeat.comWedbush Increases Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $38.00Wedbush raised their target price on Dianthus Therapeutics from $33.00 to $38.00 and gave the company an "outperform" rating in a report on Friday.May 10, 2024 | investorplace.comDNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsMay 8, 2024 | finance.yahoo.comDianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care ConferenceMay 6, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.1%Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 4.1%May 5, 2024 | americanbankingnews.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8.1%May 3, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Up 8.1%Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 8.1%May 3, 2024 | globenewswire.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Down 8.9% Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 8.9%April 18, 2024 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Dianthus TherapeuticsApril 18, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $51.00 at Raymond JamesRaymond James increased their price target on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an "outperform" rating in a research report on Thursday.April 18, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up to $23.34Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up to $23.34April 17, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6%April 15, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short InterestDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 1,390,000 shares, a growth of 29.9% from the March 15th total of 1,070,000 shares. Based on an average trading volume of 141,400 shares, the days-to-cover ratio is presently 9.8 days. Currently, 6.5% of the company's stock are sold short.April 12, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume IncreaseDianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeApril 11, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Trading 4.7% Higher Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.7%April 11, 2024 | globenewswire.comDianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual MeetingApril 8, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Down 4.7% Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.7%April 5, 2024 | globenewswire.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 5, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.9%Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.9%April 2, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 7.7%Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 7.7%March 30, 2024 | marketbeat.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest UpdateDianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 1,070,000 shares, an increase of 27.3% from the February 29th total of 840,400 shares. Based on an average trading volume of 127,100 shares, the days-to-cover ratio is currently 8.4 days. Approximately 5.0% of the company's stock are sold short.March 25, 2024 | marketbeat.comDianthus Therapeutics (NASDAQ:DNTH) PT Raised to $39.00 at Jefferies Financial GroupJefferies Financial Group upped their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a "buy" rating in a research report on Friday.March 25, 2024 | finanznachrichten.deDianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial ResultsMarch 22, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Xenetic Biosciences (XBIO) and Dianthus Therapeutics (DNTH)March 22, 2024 | finance.yahoo.comDianthus Therapeutics Insiders Added US$2.05m Of Stock To Their HoldingsMarch 22, 2024 | marketbeat.comWedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $33.00Wedbush lifted their target price on Dianthus Therapeutics from $24.00 to $33.00 and gave the stock an "outperform" rating in a research note on Friday.March 21, 2024 | globenewswire.comDianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial ResultsMarch 15, 2024 | finance.yahoo.comEQ Apr 2024 5.000 putMarch 9, 2024 | morningstar.comDianthus Therapeutics Inc DNTHMarch 8, 2024 | finanznachrichten.deDianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 7, 2024 | globenewswire.comDianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | marketbeat.comFmr LLC Makes New $28.96 Million Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Fmr LLC bought a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,218,212 shares of the company's stock, valued at approximately $28,961,000. Fmr LLC owned 58.50% of DiaFebruary 26, 2024 | finanznachrichten.deDianthus Therapeutics, Inc.: Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)February 26, 2024 | globenewswire.comDianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)February 24, 2024 | msn.comDianthus Therapeutics (DNTH) Price Target Increased by 22.22% to 35.53February 23, 2024 | ca.finance.yahoo.comSMCI Jan 2025 1310.000 callFebruary 23, 2024 | finance.yahoo.comSMCI Mar 2024 1070.000 callFebruary 23, 2024 | marketbeat.comAtlas Venture Life Science Advisors LLC Acquires New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 236,979 shares of the company's stock, valued at approximately $3,240,000February 23, 2024 | markets.businessinsider.comDianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 15, 2024 | msn.comStifel starts Dianthus at buy, cites market potential of lead drugFebruary 15, 2024 | benzinga.comDecoding 4 Analyst Evaluations For Dianthus TherapeuticsFebruary 15, 2024 | marketbeat.comStifel Nicolaus Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)Stifel Nicolaus started coverage on Dianthus Therapeutics in a research note on Thursday. They set a "buy" rating and a $44.00 target price for the company.January 31, 2024 | finance.yahoo.comDianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology ConferenceJanuary 29, 2024 | marketbeat.comEquities Analysts Set Expectations for Dianthus Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:DNTH)Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Analysts at Wedbush issued their FY2028 earnings estimates for shares of Dianthus Therapeutics in a note issued to investors on Friday, January 26th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($2January 26, 2024 | marketbeat.comWedbush Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $24.00Wedbush raised their target price on Dianthus Therapeutics from $23.00 to $24.00 and gave the company an "outperform" rating in a research report on Friday. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. DNTH Media Mentions By Week DNTH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DNTH News Sentiment▼0.070.56▲Average Medical News Sentiment DNTH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DNTH Articles This Week▼122▲DNTH Articles Average Week Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Mineralys Therapeutics News Wave Life Sciences News AnaptysBio News Nurix Therapeutics News Nuvation Bio News Bicycle Therapeutics News Savara News Disc Medicine News Phibro Animal Health News Aurinia Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DNTH) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden FINISHED On June 13th?Paradigm PressTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
